Literature DB >> 11701070

Recent-onset bell palsy complicated by diabetes: comparison of steroid and lipoprostaglandin E(1) therapy.

T Koriyama1, S Inafuku, K Kimata, T Banno, H Ishigami.   

Abstract

OBJECTIVE: To compare megadose steroid therapy (n = 17; group S) and lipoprostaglandin E(1) (lipo-PGE(1)) therapy (n = 14; group L) in patients with recent-onset Bell palsy complicated by diabetes.
DESIGN: A nonrandomized controlled trial was performed. The 2 groups were almost identical in age, sex distribution, and laterality, and there was no difference in the average palsy scores in the 2 groups either at the time of the first visit or when the palsy was at its worst.
RESULTS: There was no statistically significant difference in the cumulative rates of improvement in the 2 groups 4 weeks, 2 months, or 6 months after the first visit, revealing no difference in the therapeutic effects of the 2 agents. During the therapy, fasting blood glucose concentrations were increased in all patients in group S, whereas they were not increased in group L. Complicated diabetes was aggravated in group S, while it was not aggravated in group L.
CONCLUSIONS: Lipo-PGE(1) therapy may have improved vascular flow in the facial nerves and accelerated recovery, resulting in a rate of improvement comparable with that obtained through megadose steroid therapy. Lipo-PGE(1) is a useful treatment method for patients with Bell palsy complicated by diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701070     DOI: 10.1001/archotol.127.11.1338

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  2 in total

Review 1.  Management of peripheral facial nerve palsy.

Authors:  Josef Finsterer
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-27       Impact factor: 2.503

Review 2.  Acute Facial Nerve Palsy in Children: Gold Standard Management.

Authors:  Delphine Wohrer; Thomas Moulding; Luigi Titomanlio; Léa Lenglart
Journal:  Children (Basel)       Date:  2022-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.